^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
cobas® EZH2 Mutation Test

Company:
Roche
Type:
FDA Approved
Related tests:
The cobas EZH2 Mutation Test is a real-time allele-specific polymerase chain reaction (PCR) test for qualitative detection of single nucleotide mutations for Y646N, Y646F or Y646X (Y646H, Y646S, or Y646C), A682G, and A692V of the EZH2 gene in DNA extracted from formalin fixed paraffin embedded (FFPE) human follicular lymphoma tumor tissue specimens. The cobas EZH2 Mutation Test is intended for the identification of follicular lymphoma patients with an EZH2 mutation for treatment with TAZVERIK™ (tazemetostat), in accordance with the approved therapeutic product labeling.
Cancer:
Follicular Lymphoma
Gene:
EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)
Drug:
Tazverik (tazemetostat)
Method:
PCR
Approvals
Date
Cancer
Gene
Drug
By
Confirmatory trial(s)